DETECTING NEOPLASM

• US 20200131587A1
• Filed: 01/09/2020
• Published: 04/30/2020
• Est. Priority Date: 02/15/2008
• Status: Active Grant

• Current Assignee: Mayo Foundation For Medical Education And Research (Mayo Clinic)
• Original Assignee: Mayo Foundation For Medical Education And Research (Mayo Clinic)
• Inventors: Taylor, William R., Harrington, Jonathan J., Quint, Patrick S., Zou, Hongzhi, Bergen, III, Harold R., Smith, David I., Ahlquist, David A.
• Granted Patent: US 11,530,449 B2
• Time in Patent Office: Days
• CPC Class Codes: C12Q 1/37 involving peptidase or proteinase
• CPC Class Codes: C12Q 1/40 involving amylase
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/154 Methylation markers
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: C12Y 302/01001 Alpha-amylase (3.2.1.1)
• CPC Class Codes: C12Y 304/2107 Pancreatic endopeptidase E (3.4.21.70)
• CPC Class Codes: G01N 2333/928 acting on alpha -1, 4-glucosidic bonds, e.g. hyaluronidase, invertase, amylase
• CPC Class Codes: G01N 2333/966 Elastase
• CPC Class Codes: G01N 2560/00 Chemical aspects of mass spectrometric analysis of biological material
• CPC Class Codes: G01N 33/57407 Specifically defined cancers
• CPC Class Codes: G01N 33/57419 of colon
• CPC Class Codes: G01N 33/57438 of liver, pancreas or kidney

Abstract

This document relates to methods and materials for detecting premalignant and malignant neoplasms. For example, methods and materials for determining whether or not a stool sample from a mammal contains nucleic acid markers or polypeptide markers of a neoplasm are provided.

Claims

1. A method for characterizing a human biological sample comprising:

(a) measuring a K-ras mutation score from a human biological sample;

(b) measuring a methylation level of a CpG site of BMP3 from the human biological sample;

(c) determining whether or not the human biological sample has an elevated K-ras mutation score and an elevated BMP3 methylation status as compared to a control from a subject that does not have premalignant or malignant colorectal cancer.